Search clinical trials for: Azilsartan medoxomil placebo

Total 53687 results

Takeda

Completed

A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet

Hypertension

Japan
Takeda

Completed

A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure

Hypertension

Japan
Celltrion

Completed

A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers

Health, Subjective

Korea, Republic of
Takeda

Completed

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Argentina, Mexico, Peru, Chile
Takeda

Completed

A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation

Healthy Volunteers

Japan
Takeda

Completed

A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Male Participants

Japan
Hasten Biopharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

Essential Hypertension

China
Takeda

Completed

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Hypertension

United States, Mexico, Peru, Brazil, Argentina, Puerto Rico
Takeda

Completed

A Bioequivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Males

Japan
Daiichi Sankyo, Inc.

Completed

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Hypertension

United States, Colombia, Argentina, Peru, Brazil, Kenya, Chile, South Africa, India, Zambia, Uganda
Chelsea Therapeutics
Chiltern International Inc.

Completed

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa (NOH301)

Primary Autonomic Failure | Dopamine Beta Hydroxylase Deficiency | Symptomatic Neurogenic Orthostatic Hypotension (NOH) | Non-diabetic Neuropathy

United States, Canada
Sogo Rinsho Médéfi Co., Ltd.
Takeda

Completed

Azilsartan Circadian and Sleep Pressure

Hypertension

Japan
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Terminated

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? (ARBs CORONA II)

Covid19 | SARS-CoV Infection

Canada, France
Takeda

Completed

Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"

Hypertension

Japan
Replidyne

Completed

A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media

Otitis Media

Costa Rica, Israel
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
New York Medical College
Lundbeck LLC

Active, not recruiting

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

Postural Tachycardia Syndrome (POTS) | Fainting | Vasovagal Syncope (VVS)

United States
Takeda

Completed

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

Grade I or II Essential Hypertension

Japan
Takeda

Completed

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Daiichi Sankyo, Inc.

Completed

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Atherosclerosis
Daiichi Sankyo Co., Ltd.

Completed

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria

Japan, China
Takeda

Completed

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Hypertension

Poland, Germany, Bulgaria, Russian Federation, Serbia, Sweden, Netherlands, Estonia, Slovakia, Finland
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Diabetes Mellitus

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Kidney Disease

Germany
Yan Li

Active, not recruiting

Antihypertensive Treatment in Masked Hypertension for Target Organ Protection (ANTI-MASK)

Masked Hypertension

China
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Boryung Pharmaceutical Co., Ltd

Completed

Fimasartan Achieving SBP Target (FAST) Study (FAST)

Essential,Hypertension

Korea, Republic of
Central South University

Completed

Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers

Drug Interaction of Olmesartan in Healthy Chinese Volunteers

China
Bronx VA Medical Center
Chelsea Therapeutics

Completed

A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

Hypotension | Spinal Cord Injury

United States
Daiichi Sankyo, Inc.

Completed

Olmesartan Comparison to Losartan in Hypertensive Subjects

Hypertension

United States
Tohoku University

Completed

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT)

Chronic Heart Failure

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy

Diabetic Nephropathy | Chronic Glomerulonephritis

Japan
Daiichi Sankyo, Inc.

Completed

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Hypertension

United States
Virginia Polytechnic Institute and State University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Angiotensin II Blockade and Inflammation in Obesity (ARB)

Hypertension | Overweight | Prehypertension | Obese
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

Olmesartan Pediatric Pharmacokinetic (PK) Study

Hypertension

United States
Pfizer

Completed

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Hypertension
Daiichi Sankyo, Inc.
Shanghai Sankyo Pharmaceuticals Co., Ltd.

Completed

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

China
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Hypertension

United States
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis | Pancreatic Exocrine Insufficiency

United States
Daiichi Sankyo Co., Ltd.

Completed

Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension

Hypertension

Japan
Seoul National University Bundang Hospital

Completed

Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension (Ang(1-7))

Hypertension | Diabetes Mellitus, Type 2 | Angiotensin/Renin/Aldosterone Hypertension

Korea, Republic of
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

Hypertension

United States
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil and Diabetic Nephropathy

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria | Renal Disease

Poland, Spain, Estonia, Czech Republic, Germany, Slovakia, Netherlands
Daiichi Sankyo, Inc.

Completed

The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

Healthy
Jichi Medical University

Completed

The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)

Hypertension

Japan
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Healthy

United States

3

Subscribe